Αποτελέσματα Αναζήτησης
2 Δεκ 2020 · A significant therapeutic impact on patients with bladder cancer is found in the use of immune checkpoint inhibitor therapeutics. These therapeutics have been shown to cure some patients...
- Metrics
Metrics - Advances in bladder cancer biology and therapy -...
- Full Size Image
Full Size Image - Advances in bladder cancer biology and...
- Full Size Table
Full Size Table - Advances in bladder cancer biology and...
- Metrics
27 Νοε 2020 · Intravesical nadofaragene firadenovec was efficacious, with a favourable benefit:risk ratio, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. This represents a novel treatment option in a therapeutically challenging disease state.
21 Δεκ 2022 · Adstiladrin is the first FDA-approved gene therapy for bladder cancer. It's indicated for people with high-risk superficial bladder cancer unresponsive to Bacillus Calmette-Guérin immunotherapy.
FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer. On December 16, 2022, the Food and Drug ...
Pagliaro et al. 54 demonstrated that immunogene therapy can be safely and effectively applied in the treatment of bladder cancer by applying an adenoviral vector‐mediated wildtype P53 gene for bladder perfusion therapy in patients with high‐stage bladder cancer. Ad‐IFN/Syn3 is an adenoviral vector that induces interferon production in the ...
26 Οκτ 2023 · For muscle-invasive bladder cancer, radical cystectomy with neoadjuvant chemotherapy is the standard of care with evidence supporting trimodality therapy. Immune-checkpoint inhibitors...
The FDA approved the adenovirus-based gene therapy nadofaragene firadenovec for the treatment of localized bladder cancer.
